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INTRODUCTION
Human immunodeficiency virus (HIV) was isolated by Luc 
Montagnier and his co-workers in 1983 in the Pasteur Insti-
tute (Nobel Prize in 2008 for Physiology or Medicine), and 
soon after by Robert Gallo’s group in the USA in 1984. This 
virus is widespread worldwide nowadays. In 1986, in France, 
another type of virus (HIV-2) was isolated. This is more akin 
to Simian immunodeficiency virus (SIV), originating from the 
sooty mangabey monkey Cercocebus atys, which occurs in 
west Africa. Both types of virus can cause acquired immune 
deficiency syndrome (AIDS).
THE EPIDEMIOLOGY OF AIDS
It is estimated that in 2010 about 34 million people were 
living with an HIV infection worldwide (30.1 million adults 
— both sexes equally). The largest numbers of HIV patients, 
22.9 million, lived in sub-Saharan Africa, about 4 million lived 
in southern and south-eastern Asia and Latin America, and 
1.5 million lived in Eastern Europe. Approximately 2.7 million 
people were infected worldwide in 2010. According to the 
Polish National Institute of Public Health — National Institute 
of Hygiene, from 1985 (the beginning of the HIV epidemic) up 
to 31 December 2012, a total of 16,314 people were living 
with an HIV infection in Poland (including foreigners living 
in Poland); among them there were 5,946 intravenous drug 
users. 2,848 had been diagnosed with AIDS and 1,185 had 
died of the disease.
PATHOPHYSIOLOGY OF HIV INFECTION
HIV is a retrovirus, which belongs to the family of lenti-
viruses. Inside the capsid, there are a single-stranded RNA, 
reverse transcriptase and integrase. HIV is transmitted by 
sexual contact, blood or blood product transfusion, and ver-
tically from an HIV-infected mother to the newborn (before 
or during the birth, and by breast-feeding). In adults, about 
5–10 years pass between the primary infection and the oc-
currence of the first symptoms (Fig. 1).
HIV uses glycopeptide gp120 to attach to CD4 protein on 
helper lymphocytes, macrophages, monocytes, eosinophils, 
dendritic cells, microglia and oligodendroglia, T cell precursors 
in bone marrow and thymus. After the virus has penetrated 
into the cell (this process needs binding gp120 to CD4 and 
chemokine coreceptor), the viral single-stranded RNA genome 
is converted (reverse transcriptase) into a single-strand DNA, 
then a second complementary one is created, and subse-
quently integrated into a host chromosome by the viral inte-
grase and cellular LEDGF/p75 factor. Available antiretroviral 
agents block the replication of the virus but they are unable to 
remove its genetic material from the host nucleus. HIV replica-
tion is very dynamic — every day 109 virions are produced 
and destroyed. During reverse transcription 1 to 10 errors are 
made on one genome/replication cycle [1, 2]. 
After the incubation period, AIDS develops progressively. 
In the course of the disease, there is a significant decrease 
of CD4+ T lymphocytes count. Opportunistic diseases and 
cancer usually appear when CD4+ T cell level is lower than 
200/mm3 or 15% (deep immunodeficiency).
HIV infection stages:
 — Acute retroviral syndrome ‘mononucleosis-like syndrome’ 
— lasts for a few weeks after acquisition of the infection 
as a result of the spread of the virus with infection of 
the lymph nodes and occurs in approximately 40–90% 
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of infected adults. Typical symptoms are: fever (96%), 
lymphadenopathy (74%), pharyngitis (70%), maculopa-
pular rash (70%), and joint and muscle pain (54%); other 
symptoms are encountered in less than 15% of cases.
 — Asymptomatic phase, chronic — possible occurren-
ce: shingles, skin and mucous membrane diseases, 
fever > 1 month, diarrhoea > 3 months, peripheral 
neuropathy, pelvic inflammatory disease. During the 
chronic phase, organ damage, including cardiomyopathy, 
can occur.
 — AIDS: opportunistic infections (such as Pneumocystis 
jioverci pneumonia, Cryptosporidiosis), Mycobacterium 
avium infection, recurrent severe bacterial infection, 
recurrent Salmonella bacteremia, recurrent pneumo-
nia > 2 within 12 months; extrapulmonary tuberculosis, 
candidiasis of the oesophagus, bronchi, trachea, extra-
pulmonary histoplasmosis and cryptococcosis, inflamma-
tion of the oesophagus and ulcers associated with HSV 
infection, progressive multifocal leukoencephalopathy, 
cancer indicators (Kaposi’s sarcoma, lymphoma, invasive 
cervical cancer), encephalopathy and wasting syndrome.
HIV antibodies appear in a few weeks after the infection 
(at least eight days, on average 14–60 days, with a maximum 
of 12 weeks). Diagnosis of HIV infection in adults is performed 
by an ELISA test (sensitivity > 98% and specificity 99%) three 
months after exposure and confirmed by Western blot (higher 
specificity with lower sensitivity). New — fourth generation 
ELISA tests identify not only the HIV antibodies but also a pro-
tein p24 and can detect infection much earlier. Polymerase 
chain reaction (PCR) detection of the virus is mainly used to 
diagnose vertical infections in children aged < 18 months 
due to the presence of the mother’s antibodies (99–100% 
sensitivity and 100% specificity) [2].
IMPACT OF HIV INFECTION  
ON THE CARDIOVASCULAR SYSTEM
Patients with AIDS are at increased risk for cardiovascular 
(CV) diseases because of traditional CV risk factors that are 
commonly present. Hypercholesterolaemia/atherogenic 
dyslipidaemia, high blood pressure, and smoking are among 
them, also a proatherogenic diet, obesity, diabetes, low physi-
cal activity and, along with increasing survival of HIV-infected 
patients, unmodifiable factors like older age and male gender 
become important. It has been reported that a patient infected 
with HIV develops symptomatic atherosclerosis noticeably 
earlier; therefore HIV infection is considered an independent 
risk factor for CV disease along with other chronic inflamma-
tory states. HIV-infected patients often have low total choles-
terol and LDL-cholesterol as well as low HDL-cholesterol and 
increased triglycerides. Underlying mechanisms are varied and 
not fully elucidated. Low level of CD4+ lymphocytes T is as-
sociated with decreased apolipoprotein B [3]. LDL-cholesterol 
is smaller than normal [4] and harder to eliminate, and prone 
to oxidation (proatherogenic ‘small dense LDL’) [5]. 
Combined antiretroviral therapy results in increased 
LDL-cholesterol, and the predominance of small, dense LDL 
particles. Protease inhibitors may induce severe hypertri-
glyceridaemia with values of up to 1,000 mg/dL. Moreover, 
HIV-infected macrophages are more prone to develop athero-
sclerotic plaque. Highly active antiretroviral therapy (HAART) 
also increases blood pressure and insulin resistance, and this 
could contribute to the increased coronary artery disease 
Figure 1. The natural course of HIV infection (based on Gąsiorowski et al. [1, 2])
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Cardiomyopathy associated with HIV infection
In about 30% of patients with deep immunosuppression 
(CD4+ < 100/mL) dilated cardiomyopathy is observed, 
although the size of the heart chambers only slightly exceeds 
the normal values. These changes are accompanied by a slight 
decrease of left ventricular ejection fraction (EF = 45–54%), 
mainly due to segmental hypokinesis [1, 19]. Left ventricular 
systolic dysfunction in patients with HIV infection, initially 
clinically silent, becomes gradually symptomatic (HIV-induced 
cardiomyopathy). The etiopathogenesis of left ventricular 
failure differs: it can be a consequence of virus infection [20], 
systemic and local inflammatory reactions [21], the presence 
of autoantibodies [20], or immunodeficiency-related infec-
tions. A viral load greater than 500 copies/mL is associated 
with more than a two-fold increase of heart failure risk [22]. 
In the course of cardiomyopathy, dilatation of the left 
ventricle often coexists with mild myocardial hypertrophy 
[23], typically observed in the region of the posterior wall 
or interventricular septum [19]. Disease aetiology is not fully 
understood. Animal models show that the induction of cardiac 
damage occurs by promoting the expression of induced nitric 
oxide synthase (iNOS) caused by tumour necrosis factor-a, 
inter leukin-1 and interleukin-6 [24]. Cardiomyopathy can 
be aggravated by the use of nucleoside reverse transcriptase 
inhibitors therapy [25]. Isolated right ventricle dysfunction is 
also reported. Cardiac complications in children include di-
lated cardiomyopathy of the left ventricle and right ventricular 
hypertrophy [26].
Myocarditis and endocarditis
Myocarditis in the course of AIDS may develop due to differ-
ent aetiologies: fungal (Candida, Histoplasma, Cryptococcus, 
Aspergillus), viral (herpes simplex, cytomegalovirus), bacterial, 
tuberculosis and toxoplasmosis. Also, HIV infection itself can 
cause myocarditis [27]. Autoimmune processes and AIDS 
indicator pathogens can lead to endocarditis. Non-bacterial 
thrombotic endocarditis is possible and can be associated 
with hypovitaminosis (vitamin C) and immune deficiency pro-
gress. Bacterial endocarditis usually develops in intravenous 
drug users (Staphylococcus aureus and Streptococcus viri-
dans), and infection is located on the right heart valve (tricus-
pid valve) with subsequent lung abscesses. The HIV virus itself 
does not damage the endocardium, but endocarditis is due 
to the progressive decline of the CD4+ lymphocytes count.
The risk of arrhythmias and sudden cardiac death 
in HIV infection
Myocardial damage, autonomic neuropathy, and pharmaco-
logical treatment can cause cardiac arrhythmias. Antiretroviral 
drugs such as protease inhibitors (lopinavir and atazanavir) 
can cause QT prolongation and subsequent arrhythmias. Use 
of protease inhibitors may be associated with atrioventricu-
lar block and intraventricular conduction disturbances (left 
(CAD) risk. As a consequence, CAD risk may be doubled in 
patients treated with HAART compared to a non-infected 
cohort [6]. This risk may be especially prominent in young, 
male, heavy smokers with dyslipidaemia treated with HAART.
HIV-infected patients (adults and children) often have 
elevated inflammatory parameters in laboratory tests. Elevated 
D-dimer, interleukin-6, C-reactive protein are linked to the 
risk of CV diseases including heart failure [7]. It has been esti-
mated that the sTNF-R1 increased in HIV-infected patients is 
related to a higher risk according to the Framingham Cardiac 
Risk score [8]. The ongoing inflammatory process, along with 
the use of antiretroviral drugs (combined antiretroviral therapy 
based on protease inhibitors — up to 30–90%), results in the 
development of insulin resistance and lipid disorders [9]. In-
sulin resistance may also be a result of abnormal redistribution 
of fat tissue i.e. an accumulation of visceral fat and fat loss on 
limbs in the course of infection and treatment (lipodystrophy) 
[10]. As a consequence of insulin resistance, lipid disorders of-
ten occur in HIV-induced metabolic syndrome (about 30–40% 
of children). These mechanisms and intensive antiretroviral 
therapy are responsible for up to a three-fold increase in 
the risk of incidental diabetes in a three year follow-up [11]. 
Moreover, in HIV infection, damage to the arterial wall occurs 
as a result of the virus itself, and also the antiviral therapy [12]. 
The cross-sectional study the Fat Redistribution and Metabolic 
Change in HIV Infection study, conducted worldwide, showed 
a significant increase of the intima-media complex of arterial 
wall in HIV+ patients, independent of the lipid profile ab-
normalities [13]. A European study on lipid disorders among 
HIV-infected children is being conducted in parallel with the 
Paediatric European Network Trial of AIDS.
HIV-infected patients often suffer from autonomic nerve 
system dysfunction manifested by inadequate heart rate, faint-
ing, decreased sweating, diarrhoea, bladder dysfunction, and 
also erectile dysfunction [14].
CARDIOVASCULAR CLINICAL SYNDROMES  
ASSOCIATED WITH HIV INFECTION 
Coronary artery disease
The commonly present metabolic risk factors and vascular 
changes described above result in a 75% increase of myocar-
dial infarction risk in an HIV-infected group compared to the 
general population [15]. There is also a two-fold increase in CV 
risk (myocardial infarction, ischaemic heart disease, cerebral 
vascular events) in patients infected with HIV treated with 
antiretroviral therapy [16]. CAD occurs more frequently in 
patients treated with nucleoside reverse transcriptase inhibitors 
[17]. Myocardial infarction is more common in younger people 
with HIV. They also have less expressed typical symptoms of 
a heart attack. Retrospective observations in a cohort of young 
people infected with HIV, who had a heart attack, showed that 
despite more advanced coronary heart disease, their short-term 
prognosis was similar to the general population [18].
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bundle branch block) [28]. Pentamidine/pyrimethamine and 
trimethoprim/sulphamethoxazol that are used in the treatment 
of Pneumocystis jioverci infection can also prolong the QT 
interval. Systemic fungal therapy with amphotericin entails 
the risk of arrhythmias. QT prolongation is more evident in 
hypoxia and heart failure [29] and it can be threatened by 
subsequent polymorphic ventricular tachycardia (torsade de 
pointes). Gancyclovir may induce ventricular tachycardia [29].
Other abnormalities of the heart associated  
with HIV infection
In 20% of HIV-infected patients, pericardial effusion is de-
tected by echocardiography, and the incidence increases in 
patients with fully symptomatic AIDS (CD4+ < 100/mL). In 
4% of cases, the amount of fluid is large but cardiac tampon-
ade is relatively rare [30]. Pericarditis in HIV infected patients 
may be a result of bacterial infections — the most common 
cause is tuberculosis. Pericardial effusion/pericarditis may 
be a sign of Kaposi’s sarcoma [31] and lymphomas [32]. Tu-
mours of the heart are possible; usually these are secondary 
malignancies (Kaposi’s sarcoma, non-Hodgkin’s lymphoma). 
Abnormalities of cardiac development are observed in 
children born to mothers treated with antiretroviral therapy 
during pregnancy. Congenital heart abnormalities comprise 
small heart chambers, ventricular septum thinning, and the 
deterioration of left ventricular function (both systolic and 
diastolic) [33, 34].
In 0.5% of cases, pulmonary hypertension develops as 
a result of pulmonary artery damage associated with viral 
load. Three-year survival of these patients is approximately 
70% [35].
Damage can also affect peripheral veins and arteries. In-
fection with HIV, cytomegalovirus or tuberculosis may increase 
the incidence of aortic aneurysm and cerebral aneurysms 
[36, 37] as a consequence. Increased level of plasminogen 
activator inhibitor type 1, heparin cofactor II, protein S, and 
D-dimers may promote venous thromboembolism, which 
is more common among HIV infected patients than in the 
general population [38].
STRATEGY OF CARDIOVASCULAR PREVENTION 
IN PATIENTS WITH HIV INFECTION
Lifestyle modification
It is mandatory for all high risk patients to stop smoking 
tobacco, a well-known CV risk factor. Proper diet and mode-
rate physical activity contribute to the reduction of insulin 
resistance, lowering blood pressure, desirable blood lipid 
modification and as a consequence slow the progression 
of atherosclerosis. This is not different from the generally 
accepted recommendations for non-pharmacological risk 
reduction of CV disease [28, 39]. The increased risk of early 
atherosclerosis and its complications associated with HIV 
infection demands more vigorous implementation of CV 
prevention guidelines. It is necessary to check lipid profile 
after diagnosis of the disease and 3–6 months after initiation 
of antiretroviral therapy treatment. In children, lipid profile 
should be monitored routinely every six months. Additional 
regular sport activities are recommended, but strength sports 
(isometric) should be avoided. Parents are educated about 
healthy lifestyles and the principles of a low-fat (sometimes 
low-carb) diet, tailored to the needs of the developing child. 
Every three months the weight and height of children, waist 
circumference, body mass index, and blood pressure should 
be measured. Once a year, bone densitometry is recom-
mended together with an assessment of fat distribution [39].
Pharmacological prevention
The recommendations do not differ notably from primary 
prevention in the general population. Due to the observed 
increased risk of CV complications in HIV-infected patients, 
statins are recommended, if total cholesterol > 190 mg/dL 
and/or LDL-cholesterol > 115 mg/dL. Caution is advised due 
to possible drug interactions i.e. simvastatin is contraindicated 
if protease inhibitors are used. Rosuvastatin, if used with lopi-
navir/ritonavir, needs caution [40]. It is recommended to use 
low-dose rosuvastatin, atorvastatin to avoid the increase of 
drug concentration induced by CYP3A4 inhibition by protease 
inhibitors. The additional anti-inflammatory effect of statins 
should be taken into account. Some figures suggest that statins 
may prolong life in HIV positive patients [41]. Fibrates should 
be started if triglycerides level is > 500 mg/dL [39, 42].
SUMMARY
HIV infection is associated with accelerated development of 
CV disease and can be a challenge for an infectious disease 
specialist involved in the care of HIV-infected patients. The 
most common CV complications include: premature CAD 
and myocardial infarction, myocarditis, and dilated cardio-
myopathy. The proarrhythmic effects of some drugs used in 
antiretroviral therapy should also be taken into account. The 
efficacy of pharmacotherapy in controlling HIV infection 
results in a significant improvement in the life expectancy 
of patients infected. The new challenge in this group of 
patients involves ageing. In HIV positive patients, ageing is 
about ten years earlier than in the general population. This 
increases the likelihood of CV disease resulting not only 
from ageing but also as a consequence of HIV infection, its 
sequelae and antiretroviral therapy. Recommendations ap-
plying to CV prevention consist of lifestyle modification and 
pharmacotherapy, preferably with statins. The guidelines for 
the treatment of symptomatic CV disease do not differ from 
generally accepted standards.
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